帕博利珠单抗治疗复发性口腔舌鳞癌完全缓解：一例报告。
Complete response with pembrolizumab in recurrent squamous cell carcinoma of the oral tongue: A case report.
机构信息
Keck School of Medicine, University of Southern California, 1975 Zonal Avenue, Los Angeles, CA 90033, USA.
Division of Medical Oncology - Head and Neck, USC Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, NTT3440, Los Angeles, CA 90033, USA.
出版信息
Oral Oncol. 2023 Dec;147:106597. doi: 10.1016/j.oraloncology.2023.106597. Epub 2023 Oct 17.
Immunotherapies such as immune checkpoint inhibitors have shown promising results in solid tumors associated with BRCA2, but there are no consistent predictors for who will respond to immunotherapy. More research is needed on the impact of this mutation in head and neck squamous cell carcinomas, particularly for recurrent/metastatic tumors. We report a case of stage IV oral squamous cell carcinoma associated with BRCA2 mutation that achieved complete remission with pembrolizumab treatment for relapsed disease.
免疫疗法，如免疫检查点抑制剂，在与 BRCA2 相关的实体肿瘤中显示出有前景的结果，但目前还没有一致的预测指标来确定谁对免疫疗法有反应。需要进一步研究这种突变在头颈部鳞状细胞癌中的影响，特别是针对复发性/转移性肿瘤。我们报告了一例与 BRCA2 突变相关的 IV 期口腔鳞状细胞癌病例，该病例在复发性疾病中接受 pembrolizumab 治疗后达到完全缓解。
Zotero 插件